Related Experiment Video
Updated: Aug 10, 2025
04:59
Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
Published on: September 27, 2019
12.3K
Itch and Janus Kinase Inhibitors
Yujin Han1, Yu Ri Woo1, Sang Hyun Cho1
1Department of Dermatology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Acta Dermato-Venereologica
|February 15, 2023
Summary
Janus kinase (JAK) inhibitors offer rapid relief for chronic itch by targeting the non-histaminergic pathway. These advanced therapies show promise for various skin conditions, though potential side effects require consideration.
Area of Science:
- Dermatology and immunology, focusing on pruritus (itch) mechanisms and therapeutic interventions.
Background:
- Chronic itch is often mediated by non-histaminergic pathways, proving resistant to conventional treatments.
- The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is crucial for cytokine signaling involved in inflammatory processes.
- Understanding these pathways is key to developing novel antipruritic therapies.
Approach:
- This review analyzes current evidence on the efficacy of Janus kinase inhibitors (JAKis) for managing various types of itch.
- It examines the role of the JAK-STAT pathway in itch pathogenesis and its modulation by JAKis.
- Clinical trial data and case reports demonstrating JAKis' effectiveness are evaluated.
Key Points:
- Janus kinase inhibitors have shown significant efficacy in treating pruritus associated with atopic dermatitis, psoriasis, prurigo nodularis, and lichen planus.
- Rapid itch relief has been observed with JAKis compared to traditional therapies.
- Common adverse effects include nasopharyngitis, acne, and elevated creatine phosphokinase.
Conclusions:
- Janus kinase inhibitors represent a promising therapeutic option for difficult-to-treat chronic itch conditions.
- While effective, potential risks such as increased malignancies and cardiovascular events necessitate careful patient selection and monitoring.
- Further research is warranted to optimize JAK inhibitor use for itch management.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
9.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.1K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
230
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
230
02:26NF-κB-dependent Signaling Pathway
7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.8K
01:07MAPK Signaling Cascades
5.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.8K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
01:23Local Anesthetics: Mechanism of Action
2.3K
Local anesthetics (LAs) block sensory and motor impulses by inhibiting the sodium channels on the nerve cell membranes. This induces temporary loss of sensation, relieving pain in a specific body area.
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
2.3K